From: Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study
 | Standard arm (2EHRZ/4HR) | Isoniazid arm (2MHRZ/2MHR) | Ethambutol arm (2EMRZ/2MR) | p value |
---|---|---|---|---|
n 1 | 634 | 649 | 634 | Â |
Median peak ALT as × ULN (IQR) | 0.83 (0.56–1.35) | 0.78 (0.53–1.23) | 0.73 (0.51–1.09) | 0.0465 0.0006 |
Median time to peak ALT in arm (days) | 28 (14–84) | 28 (14–84) | 55 (14–84) | 0.9725 0.0176 |
Median time to peak ALT (days) if ≥3 × ULN | 28 (14–56) | 18 (14–56) | 28 (27–56) | 0.7555 0.6056 |
Median time to ALT < 1 × ULN2 (days) | 26 (15–42) | 28 (19–42) | 39 (30–61) | 0.5605 0.2706 |
No with peak ALT ≥ 3 × ULN and < 5 × ULN (%n3) | 21 (3.3%) | 17 (2.6%) | 11 (1.7%) | 0.2047 |
 Bilirubin > 2 × ULN | 2 (0.3%) | 4 (0.6%) | 0 (0.0%) | 0.1427 |
 INR4 >1.5 | 0 (0.0%) | 3 (0.5%) | 1 (0.2%) | 0.0987 |
No with peak ALT ≥ 5 × ULN and < 10 × ULN (%n3) | 13 (2.0%) | 16 (2.4%) | 11 (1.7%) | 0.6567 |
 Bilirubin > 2 × ULN | 1 (0.2%) | 2 (0.3%) | 1 (0.2%) | 0.7927 |
 INR4 >1.5 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |  |
No with peak ALT ≥10 × ULN (%n3) | 7 (1.1%) | 2 (0.3%) | 3 (0.5%) | 0.1647 |
 Bilirubin > 2 × ULN | 2 (0.3%) | 0 (0.0%) | 1 (0.2%) | 0.3607 |
 INR4 >1.5 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |  |
No of liver-related withdrawals | 11 (1.7%) | 7 (1.1%) | 4 (0.6%) | 0.178 |